Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Invigor Medical vs Genesis Lifestyle Medicine

Two GLP-1 desks, one scoreboard. We put Invigor Medical and Genesis Lifestyle Medicine head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 9 · Grade B+

Invigor Medical

Visit Invigor Medical Full brief →
vs
No. 422 · Grade C

Genesis Lifestyle Medicine

Visit Genesis Lifestyle Medicine Full brief →

The verdict

Invigor Medical takes this head-to-head.

Invigor Medical scores 88 to 53 on our six-factor Brief Score — An established telehealth pharmacy with a broad metabolic and hormone catalog and a steady price line.

That doesn't make Genesis Lifestyle Medicine a bad call — it's best for readers who want hybrid med-spa glp-1 with 18 clinics and brand-name access. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
87
40
Supply Reliability
88
74
Transparency
84
23
Access Breadth
82
42
Clinical Oversight
88
78
Track Record
90
70
Invigor MedicalBrief Score 88 · 53Genesis Lifestyle Medicine

Price, coverage & the tracker

Invigor MedicalGenesis Lifestyle Medicine
Brief Score88/100 (B+)53/100 (C)
Semaglutide$199/moNot disclosed
Tirzepatide$339/moNot disclosed
CoverageNot disclosed8 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

Invigor Medical: Long-running operator; mid-market pricing unchanged this cycle.

Genesis Lifestyle Medicine: New to the tracker on 1 August 2026. This program publishes no monthly medication price, so there is no line for us to track until it does.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.